Duration and mechanisms of the increased natural cytotoxicity seen after chronic voluntary exercise in rats.
We have recently shown that in vivo natural cytotoxicity is enhanced after chronic exercise in spontaneously hypertensive rats (SHRs). In the present report, we have studied the duration of this augmentation and some possible mechanisms involved. Exercise consisted of voluntary running for 4-5 weeks, with the running distance ranging from 2.7-15.6 km day(-1) during the last week of running. In vivo cytotoxicity was measured as clearance of injected 51Cr-labelled YAC-1 lymphoma cells from the lungs. The in vivo natural cytotoxicity was increased in running SHRs, and also in SHRs that had their running wheel locked for 24 and 48 h prior to the experiment, and was still present after 96 h. The enhancement of in vivo cytotoxicity after 5 weeks of exercise was abolished after an acute injection of the beta-adrenergic receptor antagonist timolol (0.5 mg kg(-1) i.v.), indicating that catecholamines are involved in this augmentation. Interestingly, 24 h after the last exercise bout, the increased natural cytotoxicity could be blocked by timolol. The opioid receptor antagonist naloxone given subcutaneously for 7 days by osmotic pumps (6 mg kg(-1) h(-1)) could not reverse the increased in vivo cytotoxicity seen in the running SHRs, suggesting that opioid receptor mechanisms are not involved, or at least not the naloxone-sensitive mu-receptor. Natural immunity was not influenced by the histamine H2 receptor antagonist ranitidine, either in controls or in runners, indicating that the natural killer cell-regulatory effect of histamine is not present in SHRs and does not seem to be involved in the exercise-induced changes in natural immune function. We conclude that the augmentation of in vivo natural cytotoxicity after voluntary chronic exercise in rats is long-lasting and that the augmentation is partly mediated by beta-adrenergic receptors.
Jonsdottir
I H
IH
Institute of Physiology and Pharmacology, Department of Physiology, Göteborg University, Sweden.
Johansson
C
C
Asea
A
A
Johansson
P
P
Hellstrand
K
K
Thorén
P
P
Hoffmann
P
P
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002395:Catecholamines / Q000502:physiology; D002470:Cell Survival / Q000502:physiology*; D006632:Histamine / Q000502:physiology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D005082:Physical Exertion / Q000502:physiology*; D011899:Ranitidine / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D013999:Timolol / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D006635:Histamine H2 Antagonists; D009292:Narcotic Antagonists; D009270:Naloxone; D013999:Timolol; D006632:Histamine; D011899:Ranitidine